Skip to content

Advertisement

Articles

Sort by
Page 1 of 24
  1. Content type: Research

    Alzheimer’s disease (AD) is a multifactorial and complex neuropathology that involves impairment of many intricate molecular mechanisms. Despite recent advances, AD pathophysiological characterization remains ...

    Authors: D. M. Vargas, M. A. De Bastiani, E. R. Zimmer and F. Klamt

    Citation: Alzheimer's Research & Therapy 2018 10:59

    Published on:

  2. Content type: Research

    Increasing evidence suggests that cerebral vascular dysfunction is associated with the early stages of Alzheimer’s disease (AD). Vascular endothelial growth factor (VEGF) is one of the key players involved in ...

    Authors: Ananya Chakraborty, Madhurima Chatterjee, Harry Twaalfhoven, Marta Del Campo Milan, Charlotte E. Teunissen, Philip Scheltens, Ruud D. Fontijn, Wiesje M. van Der Flier and Helga E. de Vries

    Citation: Alzheimer's Research & Therapy 2018 10:58

    Published on:

  3. Content type: Viewpoint

    The performance of [18F]flutemetamol amyloid PET against histopathological standards of truth was the subject of our recent article in Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring (2017;9:25...

    Authors: Milos D. Ikonomovic, Enrico R. Fantoni, Gill Farrar and Stephen Salloway

    Citation: Alzheimer's Research & Therapy 2018 10:60

    Published on:

  4. Content type: Viewpoint

    Psycho-affective states or traits such as stress, depression, anxiety and neuroticism are known to affect sleep, cognition and mental health and well-being in aging populations and to be associated with increa...

    Authors: Gaël Chételat, Antoine Lutz, Eider Arenaza-Urquijo, Fabienne Collette, Olga Klimecki and Natalie Marchant

    Citation: Alzheimer's Research & Therapy 2018 10:57

    Published on:

  5. Content type: Correction

    Upon publication of this article [1], it was noticed that there were some inconsistencies in Tables 1, 2 and 3. Some of the superscript letters were incorrectly assigned. Please see below the correct tables:

    Authors: Isabelle Bos, Frans R. Verhey, Inez H. G. B. Ramakers, Heidi I. L. Jacobs, Hilkka Soininen, Yvonne Freund-Levi, Harald Hampel, Magda Tsolaki, Åsa K. Wallin, Mark A. van Buchem, Ania Oleksik, Marcel M. Verbeek, Marcel Olde Rikkert, Wiesje M. van der Flier, Philip Scheltens, Pauline Aalten…

    Citation: Alzheimer's Research & Therapy 2018 10:56

    Published on:

    The original article was published in Alzheimer's Research & Therapy 2017 9:101

  6. Content type: Research

    Truncated mis-disordered tau protein plays an important role in the pathogenesis of Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Tau294–305, an epitope in the truncated tau, is essential for pathol...

    Authors: Mei Ji, Xi-xiu Xie, Dong-qun Liu, Xiao-lin Yu, Yue Zhang, Ling-Xiao Zhang, Shao-wei Wang, Ya-ru Huang and Rui-tian Liu

    Citation: Alzheimer's Research & Therapy 2018 10:55

    Published on:

  7. Content type: Research

    Alzheimer’s disease (AD) is characterized by physiologically endogenous proteins amyloid beta (Aβ) and tau undergoing a conformational change and accumulating as soluble oligomers and insoluble aggregates. Tau...

    Authors: Krystal Herline, Frances Prelli, Pankaj Mehta, Claire MacMurray, Fernando Goñi and Thomas Wisniewski

    Citation: Alzheimer's Research & Therapy 2018 10:54

    Published on:

  8. Content type: Research

    Synaptic and axonal loss are two major mechanisms underlying Alzheimer’s disease (AD) pathogenesis, and biomarkers reflecting changes in these cellular processes are needed for early diagnosis and monitoring t...

    Authors: Madhurima Chatterjee, Marta Del Campo, Tjado H. J. Morrema, Matthijs de Waal, Wiesje M. van der Flier, Jeroen J. M. Hoozemans and Charlotte E. Teunissen

    Citation: Alzheimer's Research & Therapy 2018 10:52

    Published on:

  9. Content type: Research

    Drugs for dementia have been available in England since 1997. Since their launch, there have been several changes to national guidelines and initiatives that may have influenced prescribing. These include chan...

    Authors: Venexia M. Walker, Neil M. Davies, Patrick G. Kehoe and Richard M. Martin

    Citation: Alzheimer's Research & Therapy 2018 10:51

    Published on:

  10. Content type: Research

    Amyloid-β (Aβ) immunotherapy is one of the most promising disease-modifying strategies for Alzheimer’s disease (AD). Despite recent progress targeting aggregated forms of Aβ, low antibody brain penetrance rema...

    Authors: Stina Syvänen, Greta Hultqvist, Tobias Gustavsson, Astrid Gumucio, Hanna Laudon, Linda Söderberg, Martin Ingelsson, Lars Lannfelt and Dag Sehlin

    Citation: Alzheimer's Research & Therapy 2018 10:49

    Published on:

  11. Content type: Research

    We investigated the effects of lifetime cumulative ginseng intake on cognitive function in a community-dwelling population-based prospective cohort of Korean elders.

    Authors: Silvia Kyungjin Lho, Tae Hui Kim, Kyung Phil Kwak, Kayoung Kim, Bong Jo Kim, Shin Gyeom Kim, Jeong Lan Kim, Tae Hyun Kim, Seok Woo Moon, Jae Young Park, Joon Hyuk Park, Seonjeong Byun, Seung Wan Suh, Ji Young Seo, Yoonseop So, Seung-Ho Ryu…

    Citation: Alzheimer's Research & Therapy 2018 10:50

    Published on:

  12. Content type: Research

    The ε4 allele of the apolipoprotein E gene (APOE-ε4) is the strongest genetic factor for late-onset Alzheimer’s disease. During middle age, cognitively healthy APOE-ε4 carriers already show several brain alterati...

    Authors: Grégory Operto, Raffaele Cacciaglia, Oriol Grau-Rivera, Carles Falcon, Anna Brugulat-Serrat, Pablo Ródenas, Rubén Ramos, Sebastián Morán, Manel Esteller, Nuria Bargalló, José Luis Molinuevo and Juan Domingo Gispert

    Citation: Alzheimer's Research & Therapy 2018 10:48

    Published on:

  13. Content type: Research

    In patients with frontotemporal dementia, it has been shown that brain atrophy occurs earliest in the anterior cingulate, insula and frontal lobes. We used visual rating scales to investigate whether identifyi...

    Authors: Giorgio G. Fumagalli, Paola Basilico, Andrea Arighi, Martina Bocchetta, Katrina M. Dick, David M. Cash, Sophie Harding, Matteo Mercurio, Chiara Fenoglio, Anna M. Pietroboni, Laura Ghezzi, John van Swieten, Barbara Borroni, Alexandre de Mendonça, Mario Masellis, Maria C. Tartaglia…

    Citation: Alzheimer's Research & Therapy 2018 10:46

    Published on:

  14. Content type: Research

    The contribution of psychological factors to brain health and resilience remains poorly investigated. Furthermore, their possible interaction with ‘classical’ cognitive reserve (CR) estimates in predicting per...

    Authors: David Bartrés-Faz, Gabriele Cattaneo, Javier Solana, Josep M. Tormos and Alvaro Pascual-Leone

    Citation: Alzheimer's Research & Therapy 2018 10:47

    Published on:

  15. Content type: Research

    The range of onset ages within some PSEN1 families is wide, and a few cases of reduced penetrance of PSEN1 mutations have been reported. However, published data on reduced penetrance have been limited to clinical...

    Authors: Steinunn Thordardottir, Elena Rodriguez-Vieitez, Ove Almkvist, Daniel Ferreira, Laure Saint-Aubert, Anne Kinhult-Ståhlbom, Håkan Thonberg, Michael Schöll, Eric Westman, Anders Wall, Maria Eriksdotter, Henrik Zetterberg, Kaj Blennow, Agneta Nordberg and Caroline Graff

    Citation: Alzheimer's Research & Therapy 2018 10:45

    Published on:

  16. Content type: Research

    The study investigated whether donepezil exerts symptomatic benefit in patients with posterior cortical atrophy (PCA), an atypical variant of Alzheimer’s disease.

    Authors: Basil H. Ridha, Sebastian Crutch, Dawn Cutler, Christopher Frost, William Knight, Suzie Barker, Norah Epie, Elizabeth K. Warrington, Riitta Kukkastenvehmas, Jane Douglas and Martin N. Rossor

    Citation: Alzheimer's Research & Therapy 2018 10:44

    Published on:

  17. Content type: Research

    Vitamin D deficiency is associated with an increased risk of Alzheimer’s disease and increased beta-amyloid (Aβ) in animals. Hence we sought to investigate the relationship between plasma 25-hydroxyvitamin D (...

    Authors: Fati Nourhashemi, Claudie Hooper, Christelle Cantet, Catherine Féart, Isabelle Gennero, Pierre Payoux, Anne Sophie Salabert, Sophie Guyonnet, Philipe De Souto Barreto and Bruno Vellas

    Citation: Alzheimer's Research & Therapy 2018 10:43

    Published on:

  18. Content type: Research

    With upcoming therapeutic interventions for patients with primary progressive aphasia (PPA), instruments for the follow-up of patients are needed to describe disease progression and to evaluate potential thera...

    Authors: Elisa Semler, Sarah Anderl-Straub, Ingo Uttner, Janine Diehl-Schmid, Adrian Danek, Beate Einsiedler, Klaus Fassbender, Klaus Fliessbach, Hans-Jürgen Huppertz, Holger Jahn, Johannes Kornhuber, Bernhard Landwehrmeyer, Martin Lauer, Rainer Muche, Johannes Prudlo, Anja Schneider…

    Citation: Alzheimer's Research & Therapy 2018 10:41

    Published on:

  19. Content type: Research

    Mild cognitive impairment (MCI) is a heterogeneous syndrome resulting from Alzheimer’s disease (AD) as well as to non-AD and non-neurodegenerative conditions. A subset of patients with amnestic MCI (aMCI) pres...

    Authors: Chiara Cerami, Alessandra Dodich, Sandro Iannaccone, Giuseppe Magnani, Roberto Santangelo, Luca Presotto, Alessandra Marcone, Luigi Gianolli, Stefano F. Cappa and Daniela Perani

    Citation: Alzheimer's Research & Therapy 2018 10:42

    Published on:

  20. Content type: Research

    Alzheimer’s disease (AD) is a devastating neurodegenerative disorder bearing multiple pathological hallmarks suggestive of complex cellular/molecular interplay during pathogenesis. Transgenic mice and nonhuman...

    Authors: Feng-Qin Zhou, Juan Jiang, Chelsea M. Griffith, Peter R. Patrylo, Huaibin Cai, Yaping Chu and Xiao-Xin Yan

    Citation: Alzheimer's Research & Therapy 2018 10:40

    Published on:

  21. Content type: Research

    Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood bi...

    Authors: Andre Strydom, Amanda Heslegrave, Carla M. Startin, Kin Y. Mok, John Hardy, Jurgen Groet, Dean Nizetic and Henrik Zetterberg

    Citation: Alzheimer's Research & Therapy 2018 10:39

    Published on:

  22. Content type: Research

    Symptomatic benefits have been reported for 5-HT6 receptor antagonists in Alzheimer’s disease (AD) trials. SAM-760 is a potent and selective 5-HT6 receptor antagonist that has demonstrated central 5-HT6 receptor ...

    Authors: Terence Fullerton, Brendon Binneman, William David, Marielle Delnomdedieu, James Kupiec, Peter Lockwood, Jessica Mancuso, Jeffrey Miceli and Joanne Bell

    Citation: Alzheimer's Research & Therapy 2018 10:38

    Published on:

  23. Content type: Research

    Comparison of disease progression between placebo-group patients from randomised controlled trials (RCTs) and real-world patients can aid in assessing the generalisability of RCT outcomes. This analysis compar...

    Authors: Catherine Reed, Mark Belger, Grazia Dell’Agnello, Kristin Kahle-Wrobleski, Gopalan Sethuraman, Ann Hake, Joel Raskin and David Henley

    Citation: Alzheimer's Research & Therapy 2018 10:36

    Published on:

Page 1 of 24